,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1189,1,5,,48413426,68851,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
1,1199,1,3,,48413426,68851,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results,Other,,
2,1205,1,4,,48413426,68851,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,Other,,
3,1208,1,3,,48413426,68851,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
4,170870,3,4,,136936500,68851,Unspecified,,,,,Percent increase in liver weight in rats when a 50 mg/Kg dose was administered,Other,3950919.0,
5,170871,4,4,,136936500,68851,Unspecified,,,,,Percent increase in liver weight in rats when administered perorally,Other,3950919.0,
6,173042,4,3,,136936500,68851,Unspecified,,,,,Percent change in high density lipoproteins cholesterol concentration in serum from hypercholesterolemic rats at dose 50 mg/kg (po),Other,3950919.0,
7,173047,3,3,,136936500,68851,Unspecified,,,,,Percent change in low density lipoproteins cholesterol concentration in serum from hypercholesterolemic rats at dose 50 mg/kg (po),Other,3950919.0,
8,173229,4,3,,136936500,68851,Unspecified,,,,,Percent change in total cholesterol concentration in serum from hypercholesterolemic rats at dose 50 mg/kg (po),Other,3950919.0,
9,193705,3,3,,136936500,68851,Unspecified,,,,,Percent change in triglyceride concentration in serum from hypercholesterolemic rats at dose 50 mg/kg (po),Other,3950919.0,
10,197580,3,3,,136936500,68851,Unspecified,,,,,Compound was tested for Enzyme induction effect in male rats treated for 5 days at dose 75 mg/kg aminopyrine N-demethylase activity(per g) of liver,Other,3950919.0,
11,197581,3,3,,136936500,68851,Unspecified,,,,,Compound was tested for Enzyme induction effect in male rats treated for 5 days at dose 75 mg/kg aniline p-hydroxylase activity(per g) of liver,Other,3950919.0,
12,197582,3,3,,136936500,68851,Unspecified,,,,,Compound was tested for Enzyme induction effect in male rats treated for 5 days at dose 75 mg/kg concentration of cytochrome P-540( mmol/mg) in protein,Other,3950919.0,
13,197583,3,3,,136936500,68851,Unspecified,,,,,Compound was tested for Hepatic peroxisomal proliferation effect in male rats treated for 7 days at dose 50 mg/kg carnitine acetyl transferase activity(per mg) of protein,Other,3950919.0,
14,197584,3,3,,136936500,68851,Unspecified,,,,,Compound was tested for Hepatic peroxisomal proliferation effect in male rats treated for 7 days at dose 50 mg/kg protein,Other,3950919.0,
15,197585,3,3,,136936500,68851,Unspecified,,,,,Compound was tested for Hepatic peroxisomal proliferation effect in male rats treated for 7 days at dose 50 mg/kg palmitoyl-CoA oxidation activity(per mg) of protein,Other,3950919.0,
16,197590,3,3,,136936500,68851,Unspecified,,,,,Compound was tested for Enzyme induction effect in male rats treated for 5 days at dose 75 mg/kg concentration of microsomal proteins(mg/g) in liver,Other,3950919.0,
17,197591,3,3,,136936500,68851,Unspecified,,,,,Compound was tested for Hepatic peroxisomal proliferation effect in male rats treated for 7 days at dose 50 mg/kg concentration of hepatic proteins(mg/g) in liver,Other,3950919.0,
18,231070,3,3,,136936500,68851,Unspecified,,,,,Percent change in high density lipoprotein cholesterol in hypercholesterolemic rats,Other,3950919.0,
19,231879,3,4,,136936500,68851,Unspecified,,,,,Compound was tested for Enzyme induction effect in male rats treated for 5 days at dose 75 mg/kg ratio of % liver weight to % body weight,Other,3950919.0,
20,231881,3,4,,136936500,68851,Unspecified,,,,,Compound was tested for Hepatic peroxisomal proliferation effect in male rats treated for 7 days at dose 50 mg/kg ratio of % liver weight to % body weight,Other,3950919.0,
21,1079931,1,1,,136936500,68851,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
22,1079932,1,1,,136936500,68851,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
23,1079933,1,1,,136936500,68851,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
24,1079934,1,1,,136936500,68851,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
25,1079935,1,1,,136936500,68851,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
26,1079936,1,1,,136936500,68851,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
27,1079937,1,1,,136936500,68851,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
28,1079938,1,1,,136936500,68851,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
29,1079939,1,1,,136936500,68851,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
30,1079940,1,1,,136936500,68851,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
31,1079941,1,1,,136936500,68851,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
32,1079942,1,1,,136936500,68851,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
33,1079943,1,1,,136936500,68851,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
34,1079944,1,1,,136936500,68851,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
35,1079945,1,1,,136936500,68851,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
36,1079946,1,1,,136936500,68851,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
37,1079947,1,1,,136936500,68851,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
38,1079948,1,1,,136936500,68851,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
39,1079949,1,1,,136936500,68851,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
40,1259407,1,1,,363898084,68851,Inactive,,,,,CCRIS mutagenicity studies,Other,,
41,1259411,1,1,,363898084,68851,Active,,,,,CCRIS carcinogenicity studies,Other,,
